论文部分内容阅读
评价新一代氟喹诺酮类药司帕沙星对耐多药肺结核病(MDRTB)的治疗作用。将80例MDRTB患者随机平分两组:治疗组用司帕沙星0.1gqn;对照组用氧氟沙星0.2gtid,疗程均为6个月,同时辅以其他抗痨药物。有效率治疗组(85%)优于对照组(80%),痰菌阴转率(77.5%)优于对照组(70%),耐药率(5%)优于对照组(17.5%),两组相比无显著性差异(P>0.05),说明司帕沙星对MDRTB有一定治疗价值。
To evaluate the therapeutic effect of sparfloxacin, a new generation fluoroquinolone, on multidrug-resistant pulmonary tuberculosis (MDRTB). 80 MDRTB patients were randomly divided into two groups: treatment group with sparfloxacin 0.1gqn; the control group with ofloxacin 0.2gtid, course of treatment were 6 months, supplemented with other anti-tuberculosis drugs. The rate of sputum negative conversion (77.5%) was better than that of the control group (70%), and the drug resistance rate (5%) was superior to that of the control group (85% , No significant difference between the two groups (P> 0.05), indicating that sparfloxacin MDRTB has some therapeutic value.